Pre Clinical Research– SPG302, SLS-005, Ketamine, Macimorelin
NU-9, RNA Aptamer, CRISPR gene therapy.
Spinogenix SPG-302
Currently Cleared For Phase 1
- Orally administered small molecule
- Penetrates blood-brain barrier
- Regenerates lost contacts (synapses) between neurons
Ketamine
Applied for orphan drug status: FDA
- Approved as a psychedelic anesthetic and for treatment-resistant depression
- Reduces over-firing of neurons and glutamate toxicity
- Increases Dopamine
- Preserves muscle function
Macimorelin
Preclinical research
- Ghrelin is often reduced in ALS patients
- Macimorelin mimics Ghrelin
- Improves survival and motor function in ALS mouse models
- Neuroprotective & anti-inflammatory
NU-9 Preclinical research
- Reduces protein misfolding and protein clumping
- Non-toxic and crosses the blood brain barrier
- After 60 days of treatment, diseased brain cells look like healthy cells
- More research needed before clinical trial can be initiated
RNA Aptamer Preclinical research
- Investigational RNA molecule
- Halts the death of motor neurons
- Preserves motor function
- Binds to glutamate receptors and prevents calcium overload within motor neurons
CRISPR gene therapy
Preclinical research
- Uses the gene-editing “scissor” tool CRISPR to delete a genetic mutation
- Ideally, without the mutated gene, cells cannot make the toxic proteins anymore- and the disease can’t develop
- Improves survival and motor function in ALS mouse models
- Neuroprotective & anti-inflammatory
